This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ERT CEO Discusses Q3 2010 Results - Earnings Call Transcript

Our forward-looking statements speak only as of the date made. We do not undertake and expressly disclaim any obligation to update forward-looking statements to reflect events or circumstances after the dates of these statements, except as required by law. You are cautioned not to place undue reliance on our forward-looking statements.

In addition to GAAP financial measures, we used certain non-GAAP financial measures that exclude charges related to amortization of the acquired intangible assets and the acquisition and other costs related to the recent acquisition of RS and related income tax effects. A discussion of the use of non-GAAP measures and the reconciliation to GAAP amounts is contained in the press release that we issued this afternoon.

I will first give highlights for the third quarter and details on new bookings and our operations. Keith will then discuss the detailed financials for the quarter. I will then provide some further comments on the business and then open the call up to questions.

The third quarter saw the first full quarter impact of our resent acquisition of RS. This has significantly increased our market opportunity and has given us a much broader set of products and services to offer to the clinical trials industry and potentially in the future to the healthcare industry.

Specifically, we now have an industry leading suite of products in respiratory diagnostics for clinical trials that encompass the primary respiratory diseases of COPD, asthma, and cystic fibrosis. We have added significant additional capabilities to our ePRO product and service lines by adding a PDA like device VIAPad as well as a pen based device VIAPen. We have also added a whole dimension to the products and services that we can offer our own proprietary diagnostic devices for clinical trials.

These devices give us an expanded approach to offer and customize product solutions using multiple modalities for the acquisition of important information in clinical trials. We believe this offers us a key strategic competitive advantage in our industry.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs